UK Markets closed

OKYO Pharma Limited (OKYO.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
11.25-0.25 (-2.17%)
At close: 4:28PM BST
Full screen
Previous close11.50
Open11.93
Bid0.00 x 0
Ask12.00 x 0
Day's range11.01 - 11.93
52-week range0.10 - 19.00
Volume162,655
Avg. volume1,304,810
Market cap75.664M
Beta (5Y monthly)0.75
PE ratio (TTM)N/A
EPS (TTM)-0.20
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    OKYO Pharma Limited ("OKYO" or the "Company") - Result of the Annual General Meeting

    THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTIONLONDON, Sept. 25, 2020 (GLOBE NEWSWIRE) -- OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that at the annual general meeting (the “Annual General Meeting”) held earlier today the proposed resolutions set out in the notice of Annual General Meeting dated 9 September 2020 were duly passed.The results of the proxy voting will be available shortly on the Company's website, https://www.okyopharma.com/news/.The person who arranged for the release of this announcement on behalf of the Company was Keeren Shah, Chief Financial Officer of OKYO.About OKYOOKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.Enquiries:OKYO Pharma LimitedWilly Simon+44 (0)20 7382 8300     Optiva Securities Limited Robert Emmet+44 (0)20 3981 4173 For further information, please visit the Company's website at www.okyopharma.com.

  • Globe Newswire

    Notice of Annual General Meeting

    LONDON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that it will hold its annual general meeting ("AGM") on 25 September 2020 at 10:00 a.m. The Notice of AGM, together with a proxy form and the Annual Report and Accounts for the year ended 31 March 2020, will be posted to shareholders today. The Notice of AGM will shortly also be available on the Company's website: www.okyopharma.comPlease note that arrangements for the AGM this year are different from the usual public company in-person format. As we expect significant restrictions on personal movement to still be in place due to Covid-19, we are utilizing the provisions in our recently adopted articles of association, which allow for the holding of the meeting virtually, on an electronic platform. Accordingly, this year's AGM will be an electronic meeting only. All voting at the resolutions at the AGM will be conducted on a poll (a requirement of our recently adopted articles of association) which means that you should submit your proxy (by post or, preferably, online voting) as soon as possible. We ask that, where possible, questions which shareholders wish to raise be submitted to info@okyopharma.com in advance.The platform that we will be using will allow shareholders the option to submit a separate poll card at the electronic meeting but, to ease administration, we request that proxies be lodged in advance wherever possible.Full details of the operation and arrangements for the AGM are set out in the Notice of AGM.About OKYO Pharma LimitedOKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.Enquiries:OKYO Pharma LimitedWilly Simon+44 (0)20 7495 2379     Optiva Securities LimitedRobert Emmet\+ 44 (0)20 3981 4173     RedChip Companies Inc.Dave Gentry+1 407-491-4498       dave@redchip.com For further information, please visit the Company's website at www.okyopharma.com

  • Globe Newswire

    OKYO Pharma Limited ("OKYO" or the "Company") - Appointment of Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board

    LONDON, Aug. 19, 2020 (GLOBE NEWSWIRE) -- OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that that Dr. Napoleone Ferrara, MD, Professor at the University of California San Diego Medical Center, has  agreed to serve on its scientific advisory board (SAB). Dr. Ferrara is a member of The National Academy of Sciences and has received numerous prestigious awards, including the Lasker Award and the Breakthrough Prize in Life Sciences. His research on understanding the role of angiogenesis and vascular endothelial growth factor (VEGF) in cancer development, led to the discovery that VEGF is a key mediator of angiogenesis associated with intraocular neovascular syndromes. This pioneering research led to the clinical development of a humanized anti-VEGF Fab (Ranibizumab, Lucentis®), which has also been approved as a therapy for neovascular age-related macular degeneration (AMD), retinal vein occlusion and diabetic macular edema. Ranibizumab and other anti-VEGF agents have had a dramatic impact on the development of therapies for these blinding disorders. When Lucentis® (Ranibizumab) received FDA approval in late June 2006, the new macular degeneration drug was celebrated as a major medical breakthrough. Dr. Ferrara’s research also led to the development and approval of humanized anti-VEGF mAbs (Bevacizumab; Avastin®) for cancer treatment, with Avastin® being one of the bestselling cancer drugs over the last two decades. Lucentis® and Avastin® collectively achieved over $9 billion in sales last year.Dr. Napoleone Ferrara stated: “I am delighted to join OKYO Pharma as a member of the SAB. OKYO’s focus on the development of long-acting GPCR agonists to treat dry eye and ocular pain is scientifically sound and promising. GPCRs are key targets for pharmacological intervention in a variety of diseases. My expertise in ocular angiogenesis should complement these efforts and I look forward to an exciting collaboration”.Willy Simon, Chairman of OKYO said: “We are very excited about Dr. Napoleone Ferrara’s addition to the OKYO team. Very few scientists have invented two different blockbuster drugs such as Avastin® and Lucentis®. Lucentis® has become one of the major blockbuster drugs to treat eye disease and Napoleone’s experience will be a huge value added to Okyo’s drug development effort.”About OKYOOKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.Enquiries:OKYO Pharma LimitedWilly Simon+44 (0)20 7495 2379     Optiva Securities Limited Robert Emmet\+ 44 (0)20 3981 4173     Investors:       Dave Gentry RedChip Companies Inc. +1 407-491-4498     dave@redchip.com    For further information, please visit the Company's website at www.okyopharma.com.